"Fenofibrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
| Descriptor ID |
D011345
|
| MeSH Number(s) |
D02.241.081.114.968.500.625 D02.355.726.305.625 D02.455.426.559.389.134.750 D02.455.426.559.389.657.654.305.625 D02.522.223.750
|
| Concept/Terms |
Fenofibrate- Fenofibrate
- Phenofibrate
- Procetofene
- Procetofen
Apo-Feno-Micro- Apo-Feno-Micro
- Apo Feno Micro
- Apo-Fenofibrate
- Apo Fenofibrate
Lipanthyl- Lipanthyl
- Lipantil
- Fenofibrat FPh
- Lipidil
- Secalip
- Supralip
- Fénofibrate Debat
- Debat, Fénofibrate
- Lipidil-Ter
- Lipidil Ter
|
Below are MeSH descriptors whose meaning is more general than "Fenofibrate".
Below are MeSH descriptors whose meaning is more specific than "Fenofibrate".
This graph shows the total number of publications written about "Fenofibrate" by people in this website by year, and whether "Fenofibrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fenofibrate" by people in Profiles.
-
Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy. Intern Med J. 2022 04; 52(4):676-679.
-
Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy. Diabetes Res Clin Pract. 2022 Apr; 186:109835.
-
Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Sci Rep. 2021 09 21; 11(1):18708.
-
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021 Jul-Aug; 18(4):14791641211032547.
-
Effects of Modified Low-Density Lipoproteins and Fenofibrate on an Outer Blood-Retina Barrier Model: Implications for Diabetic Retinopathy. J Ocul Pharmacol Ther. 2020 12; 36(10):754-764.
-
Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Res Clin Pract. 2020 Nov; 169:108450.
-
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020 08; 22(8):1388-1396.
-
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clin Chem. 2017 Jul; 63(7):1261-1270.
-
Opposite associations between alanine aminotransferase and ?-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016 May; 65(5):783-793.
-
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Sep; 58(9):2035-44.